Sustained cancer‐relevant alternative <scp>RNA</scp> splicing events driven by <scp>PRMT5</scp> in high‐risk neuroblastoma
Laurel T. Bate-Eya(University of Oxford), Nicholas B. La Thangue(University of Oxford)
Cited by 2
Related Papers
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
|Immunology and Cell Biology|2011|443
Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response
|Nature Communications|2023|115
TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism
|Cancer Research|2016|44
The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
|Communications Biology|2023|16